In the past decade, single-use bioreactors gained significant importance in manufacturing processes of monoclonal antibodies (MAbs) and recombinant proteins. The success of such technologies comes from their numerous advantages over multiuse equipment (1). Overall, disposables offer an answer to some key challenges in the biopharmaceutical industry: time to market, validation complexity, process security, production efficiency, and cost of goods. Because the same challenges apply to vaccine production, single-use bioreactors also have the potential to optimize manufacturing processes and offer further…